Roche Holding Ltd. (ADR)(OTCMKTS:RHHBY) provided latest updates on the commercial availability of ‘cobas® HBV quantitative nucleic acid’ analysis. The test is directed to be used on the cobas® systems. These new offerings expand the viral load test portfolio of company. It works on the latest molecular diagnostic platforms. The new experiment provides detailed coverage of Hepatitis B genotypes.
The details of the new experiment
The management of Roche Diagnostics stated that with the new experiment methods, clinical laboratories will have access to highly strong and effective test for examining HBV DNA. The new method requires a lower sample for testing purpose. As a result, the users will find is convenient and flexible to complete the necessary process in time. The procedure works on the viral load monitoring portfolio formulated for the cobas® 6800/8800 Systems, launched in the market in late 2014.
Benefits of new systems
The new systems of cobas, in association with viral load assay portfolio, have capacity to enhance lab efficiencies. The systems will give rapid results considered as important to take informed treatment decisions. The new products will be soon made commercially available in markets. The management of Roche Holding Ltd. (ADR)(OTCMKTS:RHHBY) announced that the new products recognize CE-Mark. However, these products are not introduced in the U.S.
Description of Cobas® 6800/8800
These systems can be defined as fully automated applications that serve as strong tools during health and microbiology tests. They are also used during blood donor screening and viral load testing. The cobas systems are designed on the famous and popular Nobel-prize winning ‘PCR technology’. The new platform offer improved automation and quick results. It is one of the most convenient testing platforms for users due to improved efficiency. These cobas that are based on Roche’s advanced platforms permit mixed batching and deliver up to 96 results in 3.5 hours. The new features allow users to conduct up to 3 tests simultaneously.